Xtant Medical HoldingsFRA:XMS -0.55%31 PB Ratio is 1.21 as of Jun. 26, 2026, which is 43% below its 10-year median of 2.13. GuruFocus rates FRA:XMS with a GF Score™ of 31/100 and a GF Value™ of €0.53. The stock has 4 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Xtant Medical Holdings ranks better than 72.59% on this metric.
Xtant Medical Holdings Inc stock PB Ratio (=1.24) is close to 1-year low of 1.24.
The historical rank and industry rank for Xtant Medical Holdings's PB Ratio or its related term are showing as below:
FRA:XMS'
s PB Ratio Range Over the Past 10 Years
Min: 1.09 Med: 2.13 Max: 23.16
Current: 1.24
During the past 13 years, Xtant Medical Holdings's highest PB Ratio was 23.16. The lowest was 1.09. And the median was 2.13.
FRA:XMS's PB Ratio is ranked better than 72.59% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.045
vs FRA:XMS: 1.24
During the past 12 months, Xtant Medical Holdings's average Book Value Per Share Growth Rate was 10.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Xtant Medical Holdings was 28.20% per year. The lowest was -63.60% per year. And the median was -4.50% per year.
Back to Basics: PB Ratio
Xtant Medical Holdings (FRA:XMS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xtant Medical Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xtant Medical Holdings PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Xtant Medical Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Xtant Medical Holdings (FRA:XMS) has a PB Ratio of 1.21 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xtant Medical Holdings and its competitors. This is 43% below median its historical median of 2.13. Over the past decade, Xtant Medical Holdings' PB Ratio has ranged from 1.09 to 23.16. According to the industry distribution chart, Xtant Medical Holdings ranks #216 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 27.4%.
Is Xtant Medical Holdings' PB Ratio too high?
Xtant Medical Holdings' current PB Ratio of 1.21 is 43% below median its 10-year median of 2.13. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 23.16. The Medical Devices & Instruments industry median PB Ratio is 2.05. Xtant Medical Holdings' value of 1.21 is 40.8% below this industry median. Based on the distribution chart, Xtant Medical Holdings ranks #216 out of 788 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xtant Medical Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' PB Ratio compare to MDAI and QTI?
According to the Medical Devices & Instruments industry distribution chart, Xtant Medical Holdings ranks #216 out of 788 companies for PB Ratio. This puts Xtant Medical Holdings in the upper half of its industry. The industry median PB Ratio is 2.05. Xtant Medical Holdings' value of 1.21 is 40.8% below this benchmark. Historically, Xtant Medical Holdings' own PB Ratio has ranged from 1.09 to 23.16 over the past decade. While the company's 10-year median is 2.13 vs. the industry median of 2.05, Xtant Medical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xtant Medical Holdings's current PB Ratio of 1.21 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Xtant Medical Holdings and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xtant Medical Holdings's current PB Ratio is 1.21, which is 43% below median its own 10-year median of 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Xtant Medical Holdings (FRA:XMS) has a current PB Ratio of 1.21. The stock's GF Value™ is €0.53, compared to a current price of €0.36 — trading 31.3% below its estimated fair value. The current PB Ratio is 1.21, which is 43% below median its 10-year median of 2.13 and 40.8% below the Medical Devices & Instruments industry median of 2.05. Xtant Medical Holdings' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Xtant Medical Holdings (FRA:XMS), the current PB Ratio is 1.21 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xtant Medical Holdings (FRA:XMS) Overvalued in 2026?
Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued.
The current stock price of €0.36 is trading 31.3% below its estimated GF Value™ of €0.53.
Key valuation signals for FRA:XMS:
PB Ratio: 1.21 (43% below median its 10-year median of 2.13)
GF Value™: €0.53 vs. price of €0.36 (31.3% below fair value)
Industry Position: 40.8% below the Medical Devices & Instruments median (#216 of 788)
No single metric tells the full story. See the FRA:XMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
31GF Score
Get the complete analysis for FRA:XMS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:XMS has been successfully added to your 
